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The computer program ASAPprime® has been used successfully for some time to predict the stability of active
pharmaceutical ingredients (APIs) in solid-dosage forms. In this study, we have demonstrated that the ASAPprime®
program can also be used to predict the slow-down in dissolution of two APIs in an immediate release tablet. The
tablets were pre-equilibrated at 25 °C at different relative humidities (30–75 %), sealed in aluminum pouches and
stored at temperatures ranging from 50–60 °C for 3, 7 or 14 days. The storage times were selected to encompass the
time needed to produce a slowdown in dissolution such that the amount of the two APIs fell below the acceptance
criteria of no less than 80 % dissolved in 20 min. Up to 6 months of stability data from a 40 °C/75%RH open dish study
were also included in the modeling. The effects of temperature (T in °K) and relative humidity (RH) were then shown to
be related to the isoconversion (IC) time by an empirical, modified Arrhenius equations, where IC is the time for the
amount dissolved to equal 80 % of the label claim. These studies showed that while the slowdown in dissolution of
API 2 was influenced more by the relative humidity than API 1, the overall slowdown in dissolution was more sensitive
to changes in temperature than changes in relative humidity. In addition to showing that ASAPprime® could be used
to model the effects of temperature and relative humidity on dissolution, the software was also used to demonstrate
that no special precautions were necessary to protect the tablets from moisture and they could be stored in Aclar
blisters®. It was also shown that the water content of the tablet was not a critical quality attribute and need not be
included in the drug product specification.
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Fig. 1 a Dissolution Profiles of API 1 under Different Storage
Conditions, in pH 1.5 Media. b Dissolution Profiles of API 2 under
Different Storage Conditions, in pH 6.8 Media
Fig. 2 Design Space showing the Conditions Studied (blue) and the
Conditions for the Predictions (green)
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The use of accelerated stability studies is a well-
established technique that has been widely used for
more than 60 years to predict the shelf life and storage
conditions of drugs and drug products (Baertschi 2007;
Huynh-Ba 2008; Karstensen 1990; Waterman & Carella
2007). Whereas the experimental approaches may vary
between studies, the general principles are the same and
are based on the extrapolation of the rate of degradation
at two or more temperatures above the intended condi-
tion, using the Arrhenius Relationship (Eq. 1).
lnk ¼ lnA− Ea
RT
ð1Þ
where k is the rate constant for the reaction, T is the
temperature, A is the collision frequency factor, Ea is the
activation energy and R is the gas constant. Equation 1
is actually a variation of the empirical relationship devel-
oped by van’t Hoff in 1887 to describe the effect of
temperature on chemical equilibria and used later by Ar-
rhenius who found that the logarithm of the rate (or rate
constant) for various reactions was proportional to the
reciprocal of the absolute temperature. Predictions of sta-
bility based on the Arrhenius relationship (Eq. 1) work
well for well-controlled homogenous systems (such as
solutions) over relatively small temperature ranges (e.g.
50 °C). However, the Arrhenius relationship is less reliable
over larger temperature ranges when the dependency of A
and Ea on T described by Eyring (Stella, 2000) results in
non-linear relationships between ln k and 1/T. Another
important source of error arises from extrapolation of the
data because the confidence interval of the predicted value
increases as the difference between the measured and pre-
dicted values increases.
Deviations from ideal behavior (Eq. 1) in more complex,
heterogenous systems, make the prediction of stability
in solid dosage forms (SDF) more difficult. However,
Waterman and co-workers (Waterman & Swanson 2014;
MacDonald 2010; Colgan & Hofer 2015; Stella 2000;
Timmerman 2003; Waterman 2011) have shown that the
predominant factor that determines the rate of degrad-
ation in solid dosage forms, in addition to temperature, is
the presence of water. That group has shown the rate of
degradation of active pharmaceutical ingredients in tablets
and other SDFs may be predicted using a modified Arrhe-
nius equation (Eq. 2), which takes into account the water
content as well as the temperature:
lnk ¼ lnA− Ea
RT
þ B RHð Þ ð2Þ
where B is the humidity sensitivity factor and RH is the
relative humidity. Having demonstrated the applicabil-
ity of various statistical approaches for the evaluation ofdata (Eq. 2) to predict the shelf life of SDFs, Waterman and
co-workers (Waterman & Swanson 2014; MacDonald
2010; Colgan & Hofer 2015; Stella 2000; Timmerman 2003;
Waterman 2011) have developed computer software
(ASAPprime®) to facilitate the calculations. This approach
relies on the measurement of the rates of degradation at
Table 1 a Temperature (T) and relative humidity (RH) conditions
used in ASAP modeling
Experiment T (°C) RH (%) Sampling Points (days)
1 60 30 0, 7, 14
2 60 50 0, 3, 7
3 60 60 0, 3
4 60 65 0, 3, 7
5 60 75 0, 3
6 50 60 0, 7, 14
7 50 65 0, 7, 14
8b 40 75 0, 3, 6c months
aAdditional stability data at 40 °C/60%RH for API 1 from a separate, unrelated
study were also included in the modeling for API 1. The inclusion of the
data does not change the overall conclusion for API 1. Data for API 2 at
40 °C/60%RH were not available
bOpen Dish Study
cOnly API 1 was tested at 6 months
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contains two independent variables (T and RH); therefore,
at least three combinations (a 3-point protocol) of T and
RH are necessary to obtain values of A, Ea and B by regres-
sion analysis or other curve fitting techniques. The greater
the number of points in the protocol the greater the reli-
ability of the estimates of the regression coefficients, and
the predicted shelf life.
If the stability of the drug product is significantly af-
fected by the presence of moisture, sealing in a water-
impermeable package (such as aluminum foil or blister)
may be required to reduce the rate of degradation by elim-
inating any further ingress of water toward the product.
Packaging in a semi-permeable container or blister may
slow down the degradation by reducing the moisture
vapor transmission rate (MTVR). However, if the product
is particularly sensitive to the presence of water, packaging
with a desiccant may be necessary. Accelerated stability
studies of SDFs are frequently conducted in so called
“open dish” studies in which the test article is exposed to
the atmosphere and equilibrates with the ambient humid-
ity. An alternative approach to understanding the effects
of humidity on the rate of degradation is to first pre-
equilibrate the SDF with an atmosphere of known RH and
then seal it in a water-impermeable pouch made of
aluminum foil. In addition to predicting the effects of
temperature and relative humidity, ASAPprime® has the
added advantage of allowing the effects of packaging inTable 2 Stability studies/conditions used for external model validati
Study T (°C) RH (%) Time Points for Validation
1 25 60 12 months
30 65 12 months
40 75 6, 12 months
2 25 60 6, 12 monthswater-impermeable or partially impermeable containers or
blisters on stability to be predicted.
Although the intended application of (ASAPprime®) is
the prediction of the rates of chemical degradation in
SDFs there is no reason that this approach cannot be ap-
plied to physical instability, because Eq. 2 is empirical
and simply a way of correlating the rate of change of any
measurable parameter of product performance as a func-
tion of time, temperature and relative humidity. Accord-
ingly, the objective of this study was to test the hypothesis
that ASAPprime® software can be used to predict the dis-
solution rate of change of the active ingredients in tablets
at the intended storage condition, based on data obtained
at elevated temperature and relative humidity. This ap-
proach is reasonable because the majority of changes in
dissolution rate of SDFs can be attributed to changes in
water content (Waterman & Swanson 2014; MacDonald
2010; Colgan & Hofer 2015; Stella 2000; Timmerman
2003; Waterman 2011). The SDF used to test the hy-
pothesis was an investigational immediate release tablet
containing two active pharmaceutical ingredients (API 1
and API 2) that had previously shown slowed dissolution
at 40 °C/75 % RH in an open dish study and enabled bet-
ter understanding of the risk to dissolution changes at
room-temperature storage.Results and discussion
Slowdown in dissolution of both APIs was observed for
tablets stored at highly elevated temperature and relative
humidity conditions, likely due to physical changes of
the SDF, no chemical degradation of either API was ob-
served under these conditions. Representative dissolution
profiles are shown in Fig. 1a, which demonstrates that the
dissolution of API 1 at 20 min decreased from an initial
value of 90.9 to 82.9 % after three days storage in an open
dish at 60 °C/60 % RH. The dissolution of API 1 decreased
to 79.9 % after storage in an open dish for 7 days at 60 °C/
65 % RH and 76.8 % after 3 days at 60 °C/75 % RH. A
similar slowdown in the dissolution of API 2 was also ob-
served (Fig. 1b).
The impact of temperature and RH (30–75 %) (T/RH)
on dissolution at long term storage conditions was eval-
uated through a number of stressed and open dish
studies. The dissolution changes at 20 min for both
APIs over long term storage are of particular interest,on
Packaging Configurations Initial Tablet Water Content
Aclar Blisters 2.1 %
Open Dish 4.1 %
Table 3 Regression coefficients for data fitted to the modified
Arrhenius equation (Eqs. 2 and 3) and the Dimensionless
equation (Eq. 4) for the two active ingredients
API ln A Ea (kcal/mol) C (x 10
-4) B (x 10-2) R2
(SD) (SD) (SD x 10-4) (SD x 10-2)
1 73.8 (5.7) 50.0 (3.9) 2.52 (0.02) 5.3 (0.8) 0.937
2 71.4 (9.7) 51.0 (6.6) 2.58 (0.03) 10.4 (1.9) 0.954
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tablets are Q = 80 % at 20 min. (The quantity, Q, as de-
fined per USP <711>, is the amount of dissolved active in-
gredient, in percent label claim). The data were analyzed
by ASAPprime® to develop a model describing the effect
of moisture and temperature on dissolution over the prod-
uct shelf life at target storage conditions. The T/RH design
space and target are shown in Fig. 2. Detailed experimen-
tal design and durations are shown in Table 1.1 The predi-
cated data from ASAPprime® modeling were compared
against real-time stability data to validate the approach
(Table 2). The experimental data used to construct the
model relating the percent dissolved to values of T and
RH were generated by pre-equilibrating the tablets at
25 °C and various values of RH (30–75 %) (Fig. 2). The
mean values for the amounts of each API dissolved (n = 3)
after 20 min are provided in Appendix 1. The data were
fitted to Eq. 2 and the value for the regression coefficientsFig. 3 Residuals for the Predicted Isoconversion Values for the Two
Active Pharmaceutical Ingredients(A, Ea, B and R
2) are shown in Table 3. The values of
0.937 and 0.954 for R2 mean that 6.3 % (API 1) and 4.6 %
(API 2) of the variance in the data for the two APIs are
not explained by the model. Figure 3 shows the residuals
obtained from the predicted values and those obtained by
experiment were randomly distributed, indicating that
there was no systematic error in the predictions.
Effects of temperature and relative humidity on
dissolution
The computer software (ASAPprime®) uses the isocon-
version method (Waterman (2011)), rather than regres-
sion analysis to calculate the values of A, Ea, B, where
the isoconversion time, IC is the time to reach the pre-
determined value for the acceptance criteria (not less
80 % dissolved after 20 min). Replacement of the rate






þ B RHð Þ ð3Þ
Equation 3 can be re-written in dimensionless terms






þ B RHð Þ ð4Þ
where C is the temperature sensitivity factor. Equation 4
allows the effects of changing T and RH to be assessed
independently of each other. The effect of changing the
atmospheric moisture from a value of RH1 to RH2 at a




¼ B RH1−RH2ð Þ ð5Þ




¼ FΔRH ¼ eB RH1−RH2ð Þ ð6Þ
where FΔRH is the factor by which the isoconversion time
(the time to reach Q = 80 %) changes for a given change
in RH (ΔRH). Equation 6 predicts that the value of FΔRH
is independent of the intital and final values of RH and
depends only on the difference. Therefore, the values of
FΔRH, for 10 % change in absolute RH (ΔRH = 10 % RH)
are 1.70 and 2.83 for API 1 and API 2, respectively. This
means that the change in isoconversion time for the two
APIs for a 10 % change in absolute RH is approximately
70 % for API 1 and approximately 183 % for API 2 at a
fixed temperature.
The effect of changing T at a fixed value of RH (ΔT) is
slightly more complicated because the value of FΔT, de-




Fig. 4 a Predicted Water Isotherm (left) and the Predicted Water Content in the Tablets after Open-Dish Storage at 25 °C/60%RH (initial water
content 4.0 %). b Predicted Water Contents in Tablets Packaged in Aclar Blisters Over 2 Years at 25 °C/60%RH with Different Initial Water Contents.
c Predicted Water Contents in Tablets Packaged in Aclar Blisters Over 2 Years at 30 °C/75%RH with Different Initial Water Contents

























That being said, the error in using a constant value of




¼ FΔT ¼ eCΔT10−4 ð10Þ
Therefore, the values of FΔT, for 10 °C change in
temperature are 12.4 and 11.0 for API 1 and API 2, re-
spectively. This means that the change in isoconversion
time for a 10 °C change in temperature for API 1 and
API 2 are approximately 1250 % and 1100 %, respect-
ively, at a fixed value of RH.
It can be shown that the combined effect changing
both T and RH (FΔT,ΔRH) can be estimated by:
Fig. 5 Relationship between the Predicted Percent Dissolved at
20 min of Both Active Pharmaceutical Ingredients after Two Years
and the Initial Water Content at 25 °C/60%RH and 30 °C/75%RH
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or
FΔT ;RH ¼ FΔT  FΔRH
¼ eBΔRH   e CΔT10−4ð Þ ð12Þ
Therefore, the combined effect of changing the storage
conditions from the accelerated conditions 40 °C/75 %
RH to the intended storage condition of 25 °C/60 % RH
(ΔT = 15 °C ΔRH = 15 % RH) predicted by the model
(FΔT × FRH) is 96.5 and 181.3, for API 1 and API 2, re-
spectively. The individual contributions from temperature
and relative humidity are as follows
API 1
FΔT ¼ 43:6 ð13Þ
FRH ¼ 2:21 ð14Þ
API 2
FΔT ¼ 38:9 ð15Þ
FRH ¼ 4:66 ð16Þ
It is clear from Eqs. 13–16 that the contribution to a
reduction in dissolution at 20 min for both drugs from
elevating the temperature is significantly greater than
the contribution from increasing the relative humidity
and that the effects of temperature on the dissolution of
both drugs is about the same. Interestingly, although the
effects of humidity change were relatively small, the ef-
fect of RH on the dissolution of API 1 (FRH = 2.21) was
much less than the effect on API 2 (FRH = 4.66). The rea-
son for the difference in the effect of water on the dissol-
ution of the two APIs is not clear; however, it does have
important implications for the stability of the tablets at
room temperature, which are discussed in the next
sections.
Effects of initial water content
The weak dependency of drug dissolution on RH (Eq. 4)
was investigated further to determine if it was necessary
to control the water content of the tablets in the drug-
product specification. The amount of water taken up by
the tablets at specific values of RH was entered into
ASAPprime® to determine the water sorption isotherm
over the entire range of RH (Fig. 4a).2 Fig. 4a shows a
sigmoidal relationship between the water content of the
tablets in which the water content increases slowly up to
50 % RH to a value of 4 % and then increases exponen-
tially to approximately 13 % at 100 % RH. Tablet water
content change on stability can also be predicted based
on the GAB parameters and given packaging configura-
tions. Figure 4b and c are examples of predicted tablet
water contents under 25 °C/60%RH and 30 °C/75%RHstorage conditions over 2 years at different initial values.
The software uses this information to predict the effect
of the water content on the dissolution of the tablets.
Figure 5 shows the anticipated effect that the amount of
drug dissolved at 20 mins after two years’ storage de-
creases and the effect is more pronounced for API 1
than for API 2, which is expected from the previous dis-
cussions described above. Although the effect of humid-
ity is much less for API 1 than API 2, the dissolution
rate drop for both APIs are primarily driven by effect of
temperature, which is more significant for API 1 than
API 2; therefore, more changes are observed in API 1
than API 2 at the end of the two-year storage and the
differences are more pronounced at 30 °C than at 25 °C.
Despite the differences in the effects of initial moisture
on the dissolution of the two APIs, ASAPprime® predicts
that the dissolution of both drugs will remain within
specification after storage (Q = 80 %) for two years at ei-
ther 25 °C/60 % RH, or 30 °C/75 % RH independent of
the initial water content up to 6.3 % water, which is the
equilibrium water content of the tablets at 75 % RH.
The equilibrium water content at 60 % RH was found to
be 4.1 %.
Stability in Aclar® blisters
Although the ASAPprime® analysis predicted some dif-
ferences in the sensitivity of the dissolution of the two
APIs to moisture, the results also indicated the effect of
RH was insufficient to warrant the need for special pack-
aging. This is supported by the results of two studies
summarized in Table 4, which show very little, if any, in-
crease in moisture content of the tablets packaged in
Aclar® blisters for three to six months at various storage
conditions. Table 4 also shows very good agreement be-
tween the observed values of water content and the
Table 4 Predicted and observed water content of tablets
packaged in Aclar® foil blisters at different storage conditions
(Temperature (T) and Relative Humidity (RH))
Study Storage Conditions Water Content (% w/w)
T (°C) RH (%) Time (months) Initial Predicted Observed
1 30 75 6 2.1 2.4 2.2
40 75 6 2.8 2.7
25 60 6 2.3 2.0
2 25 60 3 2.4 2.5 2.4
30 65 3 2.5 2.3
40 75 3 2.8 2.7
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no difference in the amounts of the two APIs dissolved
from tablets, packaged in Aclar® blisters, following stor-
age for 12 months at 25 °C/60 % RH, 30 °C/65 % RH
and 40 °C/75 % RH. Similar results were observed on a
different batch of tablets stored at the same conditions
in an open dish (Table 5). Notably, the ASAPprime® soft-
ware predicted very accurately that the change in dissol-
ution after storage of the tablets packaged in Aclar®
blisters would be insignificant after storage for 12 months
at the intended storage condition (25 °C/60 % RH). We
will continue to the monitor the stability of these formu-
lations with a view to establishing a two-year shelf life, a
period over which predictions made by the ASAPprime®
software indicated that the dissolution of the two drugs
would be well within typical specifications (Q = 80 % at
20 min) for an immediate release product.
Conclusions
In this study, we have clearly demonstrated that the
computer program, ASAPprime®, originally developed to
predict the rates of degradation of SDFs arising fromTable 5 Predicted and observed dissolution of the two active pharm
conditions of temperature (T) and relative humidity (RH)
Study Storage Conditions Amount Dissolv
T (°C) RH (%) Time (months) API 1
Initial (T0)




2b 25 60 6 92.9
25 60 12
aTablets packaged in Aclar® blisters. Initial water content 2.1 %
bOpen dish study. Initial water content 4.1 %
cNot testedchemical reactions can also be used to predict changes
in dissolution. Experiments conducted under various
conditions of elevated temperature and relative humidity
accurately predicted that the reduced rates of dissolution
of two APIs in an SDF, IR tablet seen under accelerated
conditions would not translate into any measurable
changes in dissolution over the shelf life of the product
(up to two years at 25 °C/60 % RH or 30 °C/75 % RH).
Furthermore, the software predicted accurately that no
special precautions are necessary to protect the product
from moisture and that there is no need to control the
water content of the tablets in the drug product speci-
fication. The methodology described here adds great





All chemicals and reagents, obtained from various com-
mercial sources, were reagent grade, except for the HPLC
solvents, which were HPLC grade. Deionized water was
prepared in-house.
Tablets
The article used to test the hypothesis was an investiga-
tional, solid dosage form (SDF) tablet3 containing two ac-
tive pharmaceutical ingredients, API 1 and API 2: both




Tablet dissolution testing was performed on three tablets
stored at each condition using USP Apparatus 2 in
900 mL of dissolution media at 37 °C. Due to theiraceutical ingredients after 20 min at different storage
ed (LC%)
API 2
Final (6 or 12 mo) Initial Final (6 or 12 mo)
Predicted Observed Predicted Observed
95.9 95.7 85.5 84.9 87.4
95.8 96.4 84.8 86.7
94.7 92.5 84.6 85.6
92.7 92.5 83.9 84.8
92.8 94.1 86.3 NTc NTc
92.7 93.2 84.8 87.1
Table 6 ASAP data input for API 1 – dissolution at 20 min
Time (days) T (°C) %RH %LC at 20 min SD (%)
0 60 60 98.1 0.9
3 60 60 82.9 3
0 60 75 96.2 0.9
3 60 75 76.8 3
0 40 75 96.3 0.9
90 40 75 90.9 3
180 40 75 86.7 3
0 60 30 98.4 0.9
7 60 30 90 3
14 60 30 85.6 3
0 60 50 98.1 0.9
3 60 50 87.6 3
7 60 50 85.8 3
0 60 65 97.5 0.9
3 60 65 79.9 3
7 60 65 76.4 3
0 50 60 98.1 0.9
7 50 60 92.4 3
14 50 60 88.9 3
0 50 65 97.5 0.9
7 50 65 87 3
14 50 65 76.4 3
0 40 60 96.2 0.9
90 40 60 94.8 3
180 40 60 93.7 3
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API 1 was obtained with pH 1.5 media, and the dissol-
ution profile of API 2 was obtained with pH 6.8 media.
Dissolution profiles were collected at 5, 10, 15, 20, 30,
45 and 60 min at 75 rpm and 65 rpm, respectively for
API 1 and API 2, with an “infinity spin” from 60-75 min at
200 rpm.
Sample analysis
Samples (1.5 mL) were removed and filtered immediately
through a polyvinylidene fluoride (PVDF, 10 μm,) filter at
the sampling times listed above and analyzed for API
content by HPLC. The HPLC procedure was validated
for accuracy, precision and linearity and found to be suit-
able for the intended application. The system was calibrated
using external standards containing concentrations of API
1 and API 2 equivalent to 100 % of the label claims (LC) of
each API.
Stability studies
In one set of experiments the tablets were pre-
equilibrated to constant water content at various relative
humidity (RH) values ranging from 30 % to 75 % at 25 °C
sealed in aluminum foil pouches and stored for various
periods of time (Table 2) at 50 °C and 60 °C. In a second
set of experiments tablets were stored in petri dishes
(open dish) at 40 °C/75 % RH. Detailed experimental con-
ditions and durations are listed in Table 1. The samples
were stored in calibrated stability chambers.
Water content
The water content of the tablets was determined by au-
tomated Karl Fischer titration.
Water sorption isotherm
The water sorption isotherm of the tablets was deter-
mined using a dynamic water sorption analyzer.
Data analysis
The concentrations of the dissolved APIs at each sampling
point (C1,t and C2,t) were expressed as a percentage of the
label claim (LC%1,t) (Eq. 17) and plotted against time, t to
generate the dissolution profiles (LC%1(or 2),t vs. t).




The relationships between the values of LC%1,20 and
LC%2,20, temperature (T) and relative humidity (RH)
were established by fitting the data Eq. 2 to calculate the
regression coefficients, A, Ea, and B, using the ASAP-
prime® software (version 3, FreeThink Technologies, Inc.
Montvale, NJ 06405).Endnotes
1Additional stability data at 40 °C/60%RH for API 1
from a separate, unrelated study were also included in
the modeling for API 1. The inclusion of the data does
not change the overall conclusion for API 1. Data for
API 2 at 40 °C/60%RH were not available.
2The software uses the GAB equation developed by
Guggenheim, Anderson and de Boer as described by
Timmerman (Waterman 2009) to simulate the water
sorption isotherm. The GAB Equation parameters are
provided in Appendix 2.
3The structures of the APIs and the composition of
the tablets are proprietary; however, disclosure of this
information is not necessary to understand how the
study was conducted, the hypothesis tested or the
conclusions.Appendix 1
Table 7 ASAP data input for API 2 – dissolution at 20 min
Time (days) T (°C) %RH %LC at 20 min SD (%)
0 60 60 84.9 1.1
3 60 60 77.3 3
0 60 75 84.7 1.1
3 60 75 70.5 3
0 40 75 86.3 1.1
90 40 75 80.6 3
0 60 30 85.5 1.1
7 60 30 85.5 3
14 60 30 84.2 3
0 60 50 85.9 1.1
3 60 50 80 3
7 60 50 79.3 3
0 60 65 83.4 1.1
3 60 65 76 3
7 60 65 76.3 3
0 50 60 84.9 1.1
7 50 60 83.8 3
14 50 60 82.7 3
0 50 65 83.4 1.1
7 50 65 80.8 3
14 50 65 80.8 3
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Wm C K
2.758 7.67 0.785Abbreviations
A: Collision frequency factor; API: Active pharmaceutical ingredient;
ASAP: Accelerated stability assessment program; B: Humidity sensitivity factor;
C: Temperature sensitivity factor; Ea: Activation energy; FΔRH: Factor by which
the IC changes for given change in RH at fixed T; FΔT: Factor by which the IC
changes for given change in T at fixed value of RH; HPLC: High performance
liquid chromatography; IC: Isoconversion time; IR: Immediate release;
LC: Label claim; LC%: Percentage label claim; MVTR: Moisture vapor
transmission rate; Q: USP acceptance criteria; R: Gas constant; RH: Relative
humidity; SDF: Solid dosage form; T: Temperature
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